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Summary
Objective: To investigate the effects of tissue inhibitor of metalloproteinase (TIMP)-1 and -2 on chondrocytes cultured with or without
interleukin (IL)-1β.
Design: Canine articular chondrocytes were cultured in three-dimensional (3-D) agarose constructs. Cells were distributed into each of the
two groups, those without IL-1β and those with IL-1β added to the liquid media. Each group was subdivided into three groups, based on the
presence of TIMP-1 or -2. IL-1β and TIMPs were added to liquid media bathing the 3-D constructs beginning on day 3. The liquid media and
the 3-D constructs were collected on days 9, 15, and 24, and analyzed histologically, biochemically, and immunohistochemically.
Results: Addition of TIMP-1 or -2 resulted in decreases in matrix metalloproteinase (MMP)-3 concentrations of 37 and 41%, and MMP-1
immunoreactivity of 32 and 36%, respectively, compared with the IL-1β group, on day 9. Chondrocytes in groups without IL-1β maintained
viability and produced abundant extracellular matrix (ECM). Chondrocytes in IL-1β groups appeared less viable and produced less
ECM compared with those without IL-1β. Glycosaminoglycan (GAG) concentrations in 3-D constructs (GAG/weight) were significantly
(P<0.001) higher in groups without IL-1β than in those with IL-1β, on days 15 and 24.
Conclusions: The addition of TIMP was not detrimental to chondrocytes, as used in this study. Despite evidence of decreased MMP levels,
TIMPs did not prevent IL-1β-associated changes in cellular or ECM characteristics. Further study is necessary before clinically relevant
conclusions can be drawn regarding the use of TIMPs in the treatment of osteoarthritis.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Tissue inhibitors of matrix metalloproteinases (TIMPs) are
known endogenous protease inhibitors that bind to active
matrix metalloproteinases (MMPs) in a 1:1 molar ratio
stoichiometry1,2. Although the pathogenesis of osteo-
arthritis (OA) is not fully understood, MMPs derived from
chondrocytes, synovium, and polymorphonuclear leuko-
cytes have been proposed to play a major role in cartilage
degradation seen in OA3,4. The balance between MMPs
and TIMPs is tightly controlled in healthy joints. However, in
OA, the amount of MMPs exceeds the locally available
TIMPs, resulting in excessive extracellular matrix (ECM)
degradation5,6. Hence, MMPs have been considered
as potential targets for therapeutic strategies for OA.
Therapeutic strategies for MMP regulation can include
control of synthesis and secretion of MMPs, inhibition of
conversion of the latent form, proMMPs, to active form
MMPs, and direct inhibition of active MMPs7,8. TIMPs
provide a potential therapeutic modality for decreasing the
detrimental effects of MMPs through direct inhibition.
Inhibition of metalloproteinase activities has been
reported in chondrocyte culture9,10, cartilage explant
culture11–15, and animal11,16 studies using MMP inhibitors,
including tetracycline16, chemically derived MMP inhibi-
tors (1,10-phenanthroline, EDTA, razoxane, and 6,7-
dihydroxycoumarin)9–11, bacterially derived MMP inhibitor
(actinonin)9, and physiological MMP inhibitors (TIMP-1 and
-2)9,12,15. Hughes et al.9 reported that more than 90% of
MMP activity in conditioned media from porcine chondro-
cytes cultured in the presence of interleukin (IL)-1α was
inhibited by incubation with human recombinant TIMP-1
(255 nM) or TIMP-2 (285 nM). Bonassar et al.12 reported
that addition of 4 µM TIMP-1 to the culture media of bovine
cartilage explants inhibited IL-1β-induced loss of tissue
sulfated glycosaminoglycan (GAG) by 40% after 8 days in
culture. Ellis et al.15 reported that both TIMP-1 and -2
completely prevented the release of collagen fragments
from bovine nasal cartilage exposed to IL-1α. MMP-
induced degradation and release of GAG and collagen
fibrils from articular cartilage are hallmarks of OA. The lack
of GAG comprising proteoglycan aggrecan in osteoarthritic
articular cartilage exacerbates insufficient compressive
stiffness properties, and the damage to collagen fibrils
results in less effective tensile strength of the tissues,
leading to further mechanical disruption of the cartilage
even under physiological loads. Developing therapeutic
interventions that alter the progression of OA is critical, and
the use of TIMPs would appear to be a potentially effective
strategy.
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However, to the authors’ knowledge, data are lacking in
the literature with regard to the long-term effects of exogen-
ous TIMPs on cellular and extracellular characteristics of
chondrocytes. The present study was designed to elucidate
the temporal effects of TIMP-1 and -2 on chondrocytes
cultured with or without IL-1β, over a 3-week period, using
a three-dimensional (3-D) agarose gel culture system.
Materials and methods
COLLECTION OF SAMPLES
Full-thickness articular cartilage slices (n5) were
aseptically obtained from the caudocentral portion of the
humeral head of five canine cadavers (age range, 12–24
months) via arthrotomy performed immediately after eutha-
nasia. The dogs were euthanatized for reasons unrelated
to this study, and were apparently healthy with grossly
normal humeral head cartilage.
CHONDROCYTE CULTURE
Canine chondrocytes were isolated and cultured in
monolayer for amplifying cell number prior to placement in
3-D agarose gel, as previously reported17–19. At near
confluency in monolayer culture, media (RPMI 1640 con-
taining penicillin (100 IU/ml)/streptomycin (100 µg/ml)/
amphotericin B (2.5 µg/ml) plus 10% fetal bovine serum
(RPMI-FBS)) were discarded, the flasks rinsed, and the
cells detached by trypsinization, washed in Hank’s
balanced salt solution (HBSS), resuspended in RPMI-FBS,
and counted and checked for viability by trypan blue
exclusion. Greater than 95% cell viability was ascertained
in each sample. Equal volumes of 2% low-melting agarose
(Fisher Scientific, Fair Lawn, NJ) (gelling temperature
25±5°C) in phosphate buffered saline and double-strength
RPMI containing 20% FBS were added to produce a
cell concentration of 106 cells/ml. One milliliter of the cell
suspension was added to the wells of a 24-well tissue
culture plate. The plates were placed in a refrigerator at 4°C
for 5 min. After the agarose medium was gelled to form the
3-D construct, 1 ml of RPMI-FBS liquid media was added to
each well. The plates were incubated at 37°C with 5% CO2
and 95% humidity. Recombinant human TIMP-1 (255 nM/
ml; T1; Calbiochem, San Diego, CA), TIMP-2 (285 nM/ml;
T2; Calbiochem, San Diego, CA), IL-1β (20 ng/ml; Upstate
Biotechnology, Lake Placid, NY), IL-1β plus TIMP-1 (IL/T1),
or IL-1β plus TIMP-2 (IL/T2) were added to liquid medium
bathing the 3-D constructs, beginning on day 3 of 3-D
culture and refreshed every 3 days. In the present study,
the samples were divided into two groups based on the
presence or absence of IL-1β. For determination of the
effects of TIMP-1 and -2, each group was subdivided into
three groups based on the presence of TIMP-1 or -2. The
chondrocytes cultured in media (RPMI-FBS), with no IL-1β
or TIMP, served as controls.
SAMPLE COLLECTION
On days 9, 15, and 24 of 3-D culture, samples of liquid
media were collected and stored at −80°C for subsequent
evaluations for GAG and MMP-3 concentrations. The 3-D
construct in each well collected on days 9, 15, and 24 was
divided into two portions. One portion was placed in 10%
buffered formalin for histologic processing. The other por-
tion was lyophilized, weighed, and stored at −20°C for
subsequent evaluations for DNA, GAG, and hydroxyproline
(HP) contents.
HISTOLOGIC EVALUATION
After routine histologic processing, 5 µm sections were
stained with hematoxylin and eosin (H&E) and toluidine
blue. Sections were subjectively evaluated in duplicate by
two investigators (KK, JLC), who were unaware of collec-
tion day or group. Sections were evaluated for cellular
characteristics of viability and morphology, and for ECM
staining.
IMMUNOHISTOCHEMICAL EVALUATION
Unstained 5 µm sections were deparaffinized and rehy-
drated. Endogenous peroxidase activity was quenched by
immersion in 3% H2O2 in methanol. After antigen retrieval
treatment using trypsin for MMPs and type II collagen and
boiled citrate buffer for type I collagen, non-specific binding
was blocked with normal blocking serum. Slides were
incubated overnight at 4°C for collagen type II (rabbit,
anti-bovine) (Chemicon International Inc., Temecula, CA)
(1:400 dilution), MMP-1 (mouse, anti-human) (Calbiochem,
San Diego, CA) (1.0 µg/ml), MMP-13 (mouse, anti-human)
(Calbiochem, San Diego, CA) (2.0 µg/ml), and at 37°C for
collagen type I (goat, anti-human) (Chemicon International
Inc., Temecula, CA) (1:150 dilution). The following day, the
slides were incubated with biotinylated secondary antibody
(DAKO, Carpinteria, CA). Bound primary antibody was
detected using an avidin–horseradish peroxidase method
with diaminobenzidine (DAB) chromogenic substrate
(DAKO, Carpinteria, CA). Each antibody’s specificity for
canine cartilage tissues has been verified by immunohisto-
chemistry, as reported elsewhere20–22. Each MMP anti-
body is reported to recognize latent and active forms
without cross-reacting with other MMPs. Sections were
counterstained with hematoxylin solution. Sections were
subjectively examined by two investigators (KK, JLC), who
were blinded as to the origin of each section evaluated.
One hundred cells were counted on each slide, and the
number of definitively positive-stained cells was recorded
as percent-immunoreactivity.
MATRIX METALLOPROTEINASE-3 ASSAY
MMP-3 concentration in the liquid media was quanti-
tated by enzyme linked immunosorbent assay (ELISA)
(Calbiochem, San Diego, CA). The stored media were
thawed and then assayed for MMP-3 content according to
manufacturer’s instructions. As reported19, this ELISA has
been successfully utilized to determine MMP-3 concen-
trations in the liquid medium of cultured canine chondro-
cytes. The assay detects both latent and active MMP-3, but
does not recognize MMP-3/TIMP complex. Sample con-
centrations determined from the calculated control curve
were used for data analysis. MMP-3 concentration was
reported in ng/ml.
GLYCOSAMINOGLYCAN ASSAY
Total sulfated GAG content was quantitated by dimethyl-
methylene blue (DMMB) assay23. The 3-D samples were
digested in 1 ml of 0.5 mg/ml papain (Sigma, St. Louis, MO)
(14 U/mg) in 20 mM sodium phosphate buffer (pH 6.8)
containing 1 mM EDTA at 60°C overnight. A 10 µl aliquot of
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the digest solution was assayed for total GAG content by
addition of 240 µl of DMMB solution and by spectrophoto-
metric determination of absorbance at 525 nm. Known
concentrations of bovine trachea chondroitin sulfate A
(Sigma, St. Louis, MO) were used to construct the standard
curves. Total GAG content in 3-D samples was reported
in GAG/weight (µg/mg) and GAG/DNA (µg/µg). GAG
concentrations in the liquid media were reported in µg/ml.
DNA ASSAY
Aliquots of the papain digests prepared for DMMB assay
were utilized for DNA quantification, using a diphenylamine
assay24. A 10 µl aliquot of the digest solution was mixed
with acetaldehyde/perchloric acid followed by addition of
diphenylamine. Known concentrations of calf thymus DNA
(Sigma, St. Louis, MO) were used to construct the standard
curve. Absorbance of each sample was read at 595/700 nm
using a spectrophotometer.
HYDROXYPROLINE ASSAY
Total collagen content in 3-D constructs was determined
by measuring the HP content using a colorimetric pro-
cedure25. The papain digest solution prepared for DMMB
assay was utilized for HP assay. A 100 µl aliquot of the
digest solution was hydrolyzed with sodium hydroxide by
autoclaving. The hydrolyzate was mixed with chloramine
T reagent, followed by reaction with Ehrlich’s aldehyde
reagent. The sample was incubated at 65°C for 20 min to
develop a chromophore. Known concentrations of HP
(Sigma, St. Louis, MO) were used to construct the standard
curve. Absorbance of each sample was read at 550 nm
using a spectrophotometer. HP content in 3-D constructs
was reported in HP/weight (µg/mg).
STATISTICAL ANALYSIS
All assays were performed in duplicate. All statistical
analyses were performed using a computer software pro-
gram (Sigma Stat®, San Rafael, CA). Data from each
collection day in each group were combined, and
means±standard errors (S.E.M.) were determined. A t-test
was performed to determine differences between groups
with IL-1β and without IL-1β, with respect to concentrations
of DNA, GAG, and HP at each sample collection time.
Significance was set at P<0.05. One-way ANOVA was
performed to determine differences among all treatment
groups with respect to each assay at each collection time.
When significant differences among groups were obtained,
an all-pairwise multiple comparison was performed to
determine which groups were different from each other.
Differences within a group with respect to each assay at
different collection times were analyzed in similar manner.
Results
HISTOLOGIC EVALUATION
It is known that TIMPs can have a direct inhibitory effect
on MMP activity. However, information regarding the effects
of TIMPs on chondrocytes is lacking. We, therefore, evalu-
ated cellular morphology to determine whether addition of
TIMP-1 or -2 had effects on chondrocytes cultured in the
presence or absence of IL-1β. Chondrocytes from all dogs
were successfully cultured in the 3-D agarose culture
system for the study duration. Chondrocytes in the control
appeared round to oval, with round basophilic nuclei at all
sample points. Chondrocytes in T1 and T2 groups showed
characteristics similar to that of the controls, as determined
by H&E-stained histomorphology (data not shown). Those
chondrocytes exposed to IL-1β (IL-1β, IL/T1, IL/T2) varied
in size, but a subjectively larger percentage of IL-insulted
chondrocytes were small cells with dense nuclei com-
pared with those cultured without IL-1β (controls, T1, T2).
Temporal matrix formation was examined by toluidine blue
staining. Purple-stained pericellular and territorial matrix
were evident in chondrocyte cultures without IL-1β, indicat-
ing the presence of abundant proteoglycan synthesis in
those groups [Fig. 1(A–C)]. Toluidine blue-stained matrix
in groups cultured without IL-1β increased in size and stain
intensity consistently throughout the study period. In
Fig. 1. Photomicrograph of a section of chondrocytes in 3-D culture from control (A), T1 (B), T2 (C), IL-1β (D), IL/T1 (E), and IL/T2 (F) on
day 15, isolated from same cartilage tissue demonstrating various cell and ECM differentiations among treatment groups. It is to be noted
that matrix formation and staining are more prominent in groups without IL-1β (A, B, C) compared with those with IL-1β (D, E, F).
Chondrocytes cultured with IL-1β showed wide variety of cellular characteristics within a section, from those chondrocytes that appear less
viable (pyknosis, karyorrhexis) (D), clustered chondrocytes and matrix with a lack of proteoglycan (E), to chondrocytes with stunted matrix
(F). Toluidine blue stain; bar=50 µm.
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contrast, chondrocytes in groups with added IL-1β showed
a variety of cell and matrix characteristics, including py-
knotic chondrocytes, as shown in Fig. 1D, clustered
chondrocytes with a lack of proteoglycan, as shown in Fig.
1E, and chondrocytes with small amounts of toluidine
blue-stained matrix, as shown in Fig. 1F. The IL-1β group
exhibited histologic characteristics of loss of cell viability,
including nuclear pyknosis and lysis, more frequently than
other groups. The histologic evaluations suggested that
addition of TIMPs did not disturb cellular viability or matrix
synthesis, nor did TIMPs prevent the detrimental effects of
IL-1β on chondrocytes in this model.
IMMUNOHISTOCHEMISTRY
Decreased production, increased degradation, or both
could be responsible for the inferior ECM formation noted in
IL-insulted groups in this study. In addition, a study objec-
tive was to determine the effects of TIMPs on collagen
synthesis. To address these questions, type I and II colla-
gen immunohistochemistries were conducted using avidin–
peroxidase staining method. Both type I and II collagens
were evident in matrix by immunohistochemical assess-
ment in each group at all sample collection times. A sparse
number of chondrocytes were immunostained by anti-
collagen type I, and there were no significant differences in
the number of positive-stained chondrocytes among
groups or within any group throughout the study period.
When detected, positive type I collagen expression was
noted in pericellular matrix, as shown in Fig. 2A. It has been
reported that small amounts of type I collagen are present
in 3-D cultures of chondrocytes, previously cultured in
monolayer26,27. Therefore, it is likely that positive collagen
type I immunostaining in this study resulted from pheno-
typic changes during monolayer culture and not from the
effects of IL-1β or TIMPs.
Type II collagen was present in pericellular and territorial
matrix of chondrocytes, as shown in Fig. 2B, in all groups.
The number of positive-stained chondrocytes significantly
(P<0.01) increased within each group between days 9
and 15 of 3-D culture (Fig. 3). Collagen type II percent-
immunoreactivity was not significantly different among
groups at any sample collection time. However, the number
of type II collagen positive chondrocytes significantly (P
0.003) decreased in the IL-1β group between days 15 and
24 of 3-D culture (Fig. 3). The results suggest that IL-1β
had little effect on initial chondrocyte redifferentiation in 3-D
agarose, but resulted in loss of type II collagen after ECM
was established in this model. A significant protective effect
on IL-mediated type II collagen loss by addition of TIMP-1
or -2 could not be demonstrated in this study.
MMPs play a pivotal role in ECM degradation. MMP-1
and -13 immunohistochemistries were used to determine
whether IL-1β induces abnormal increases in MMPs in 3-D
cultured chondrocytes, and if so, whether the addition of
TIMPs would be capable of preventing detrimental effects
of increased MMPs. MMP-1 and -13 were chosen because
of their known capability for cleaving chains of native triple
helical collagens and their reported involvement in cartilage
degradation in OA22,28. Chondrocytes from all groups were
successfully stained with MMP-1 and -13 mouse anti-
human monoclonal antibodies. MMP-13 was recognized in
a sparse number of cells on days 9 and 15, consisting
primarily of nuclear staining, as shown in Fig. 4A. No
significant differences in MMP-13 percent-immunoreactivity
were found among or within groups. MMP-1 expression
was localized in the cytoplasm, as shown in Fig. 4B, of
moderate numbers of cells in each group on each sample
collection day. Significant differences (P0.038) in MMP-1
percent-immunoreactivity among treatment groups were
noted only on day 9 (Fig. 5). On day 9, the chondro-
cytes positively stained with anti-MMP-1 were significantly
Fig. 2. Photomicrograph of a section of chondrocytes in 3-D culture on day 15. (A) Chondrocytes from IL/T2 demonstrating collagen type I
staining in pericellular matrix. (B) Chondrocytes from control demonstrating collagen type II staining in pericellular and territorial matrix.
Avidin–biotin–peroxidase stain; bar=20 µm.
Fig. 3. Mean (±S.E.M.) positive collagen type II immunoreactivity in
100 cells (%) in 3-D cultured chondrocytes. The number of
positive-stained chondrocytes was significantly (P<0.01) increased
within each group between days 9 and 15. No significant differ-
ences were noted among groups at any sample collection day.
However, the number of type II collagen positive chondrocytes
significantly decreased in the IL-1β group between days 15 and 24
(P0.003).
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(P0.026) decreased in the IL/T2 group compared with the
IL-1β group, and a similar trend was seen in IL/T1 group
compared with the IL-1β group (P0.066). MMP-1 percent-
immunoreactivities in IL/T1 and IL/T2 groups were 32 and
36% lower than those in the IL-1β group, respectively.
These data suggest that addition of IL-1β induced
increased MMP-1 production by chondrocytes, but did
not influence MMP-13 levels as determined in the
present study. Addition of TIMP-1 and -2 appeared to
dampen IL-mediated increases in MMP-1 immunoreac-
tivity. Relatively high numbers of MMP-1 positive chondro-
cytes in non-IL-1β exposure groups (control, T1, T2) may
indicate a primary role for MMP-1 in matrix remodeling
during redifferentiation and establishment of ECM
by chondrocytes in 3-D agarose culture. Lower MMP-1
immunoreactivity in the IL-1β group later in 3-D culture may
be related to a loss of cell viability and synthetic activity.
MATRIX METALLOPROTEINASE ENZYME LINKED IMMUNOSORBENT
ASSAY
MMP-3 is known to degrade a wide spectrum of ECM
macromolecules, including aggrecan29. In an attempt to
elucidate the histochemical findings in this study with
respect to differences in amount and intensity of toluidine
blue-stained matrix among groups, MMP-3 concentrations
were determined in the liquid media using ELISA. MMP-3
concentrations in the liquid media were significantly (P
0.042) different among groups on day 9 (Fig. 6). The IL-1β
group had significantly (P<0.05) higher MMP-3 con-
centrations compared with the groups not exposed to
IL-1β (control, T1, T2). Although there were no significant
differences in MMP-3 concentrations among the groups
exposed to IL-1β (IL-1β, IL/T1, IL/T2), addition of TIMP-1
Fig. 4. Photomicrograph of a section of chondrocytes in 3-D culture on day 15. Chondrocytes from IL/T2 demonstrating MMP-13 (A) and
MMP-1 (B) staining in an area of cytoplasm and occasional nucleus. Avidin–biotin–peroxidase stain; bar=60 µm.
Fig. 5. Mean (±S.E.M.) positive MMP-1 immunoreactivity in 100 cells
(%) in 3-D cultured chondrocytes. MMP-1 immunohistochemistry
was performed on days 9, 15, and 24 of 3-D cultured chondro-
cytes. The number of chondrocytes positively stained with anti-
MMP-1 was significantly higher in the IL-1β group than in the IL/T2
group (*P0.026) on day 9, and a similar trend was seen between
the IL-1β group and the IL/T1 group (P0.066).
Fig. 6. Mean (±S.E.M.) MMP-3 concentrations in liquid media.
Concentrations of MMP-3 were measured on days 9, 15, and 24 of
culture media, as determined by ELISA. The IL-1β group had
significantly higher MMP concentrations compared with the groups
not exposed to IL-1β (control, T1, T2) on day 9 (*P<0.05).
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and -2 decreased MMP-3 levels compared with the IL-1β
group by 37 and 41%, respectively. No other statistically
significant differences among groups or within a group were
noted. The results suggest that IL-1β treatment increased
synthesis of MMP-3 early in 3-D culture. These data also
suggest that exogenous TIMP-1 and -2 may bind to MMP-3
and suppress MMP-3 concentrations in the liquid media of
3-D chondrocyte cultures insulted with IL-1β.
GLYCOSAMINOGLYCAN ASSAY
To verify proteoglycan production as assessed by histo-
chemical analysis, total GAG in the 3-D constructs was
measured by DMMB assay. The results for GAG in 3-D
normalized to construct weight (GAG/weight) corresponded
well with the histochemical findings regarding toluidine
blue-stained matrix formation. GAG in 3-D constructs
increased significantly (P<0.001) during the study period
within each group, except for groups IL-1β and IL/T2 [Fig.
7(A)]. There were significant (P<0.01) differences in GAG/
weight among groups on days 15 and 24 [Fig. 7(A)].
Groups without IL-1β had significantly (P<0.001) higher
GAG content than those with IL-1β. No significant differ-
ences were found among groups exposed to IL-1β or
among groups without IL-1β exposure.
To test whether an increase or a decrease in cell num-
bers may be responsible for the differences in amount of
measured GAG, total DNA in 3-D constructs was deter-
mined by diphenylamine assay. There was no statistically
significant difference in DNA content among groups on any
collection day (data not shown). Close similarities were
noted between the results of GAG content, as measured by
GAG/weight and GAG/DNA [Fig. 7(B)], suggesting that the
differences between groups not exposed to IL-1β and
groups exposed to IL-1β did not stem from either cell
proliferation or cell death.
Because differences in GAG content among groups
could be due to decreased production, increased degrada-
tion, or both, GAG concentrations in the liquid media were
also examined by DMMB assay. No significant differences
in GAG concentrations (µg/ml) in the liquid media were
noted among groups, except on day 9 (P0.038). GAG
concentrations in the liquid media were significantly (P
0.015) lower in the IL-1β group than in control on day 9
(Fig. 8). To delineate if these findings were due to increased
degradation or matrix turnover associated with GAG pro-
duction, ratios of GAG concentrations in the liquid media to
GAG in corresponding 3-D constructs were compared
among groups. There were no significant differences in the
ratios, GAG in the liquid medium:GAG in the 3-D, among
groups (data not shown), indicating that GAG concen-
trations in the liquid media were reflective of matrix turnover
of 3-D cultured chondrocytes. These results indicate that
the addition of IL-1β inhibited GAG synthesis by chondro-
cytes in this system, and addition of either TIMP-1 or -2 did
not effectively counteract this inhibition.
HYDROXYPROLINE ASSAY
The effects of IL-1β and TIMPs on collagen production
were examined by HP assay. Both the groups contained
measurable levels of HP in 3-D constructs at all sample
times. HP content (HP/weight) was significantly (P<0.05)
Fig. 7. Mean (±S.E.M.) GAG concentrations in 3-D constructs.
Concentrations of GAG were measured on days 9, 15, and 24 of
culture. (A) GAG in 3-D normalized by dry weights (GAG/weight)
and (B) GAG in 3-D per DNA (GAG/DNA). GAG contents were
significantly higher in non-IL-1β exposure groups (control, T1, T2)
than those cultured with IL-1β (IL-1β, IL/T1, IL/T2) on days 15 and
24 in GAG/weight (A) and on day 24 in GAG/DNA (B) (P<0.05).
Close homology between GAG/weight and GAG/DNA indicated
that the results were not stemmed by either an increase or
decrease in cell number.
Fig. 8. Mean (±S.E.M.) GAG concentrations in liquid media on day 9.
Concentrations of GAG were measured on days 9, 15, and 24 of
culture media. GAG concentrations in the liquid media were
significantly higher in the control than in the IL-1β group on day 9
(*P0.015).
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different among groups on each sample collection day. HP
content in 3-D was significantly (P<0.05) higher in controls
than the T2 group at each sample collection time. On day
24, in addition to the T2 group, groups IL-β and IL/T2 had
significantly (P<0.05) lower HP content than controls (Fig.
9). Consistent with the results of collagen type II immuno-
histochemistry, HP content in the IL-1β group significantly
(P<0.001) decreased between days 15 and 24. The results
of HP assay in this study suggest that exogenous IL-1β and
TIMP-2 had negative effects on collagen content.
Discussion
To date, four TIMPs, TIMP-1, -2, -3, and -4, have been
identified in mammals. TIMPs are glycoproteins composed
of two main domains: the N-terminal domain and the
C-terminal domain, stabilized by six sulfide bonds30. The
inhibitory mechanism of TIMPs on MMPs is not fully under-
stood. However, it has been reported that TIMPs inhibit
MMP on a 1:1 basis by forming high-affinity complexes1,2.
Both domains, but mainly the N-terminal domain, are
thought to contribute to the inhibitory activity against MMPs
by forming a stable native molecule31. Hughes et al.9
reported strong inhibition of MMP activity by both TIMP-1
and -2 in conditioned media of cultured porcine chondro-
cytes exposed to IL-1α. Concentrations of TIMP-1 (255 nM)
and TIMP-2 (285 nM) in the present study were adapted
from the study by Hughes et al.9, in which TIMPs used at
these concentrations were reported to have strong inhibi-
tory effects on MMPs. In the present study, neither TIMP-1
nor TIMP-2 appeared to prevent detrimental effects of IL-1β
on canine chondrocytes cultured in 3-D agarose, despite
evidence for decreases in MMPs in both the ECM and
liquid media.
Although any in vitro model is inherently non-physiologic,
the 3-D agarose culture system has been used for investi-
gating characteristics of articular chondrocytes, as it per-
mits maintenance of cell viability, differentiation, and
appropriate ECM production26,32,33. IL-1 has been used to
create in vitro models of OA because of its known involve-
ment in inciting and perpetuating this disorder19,34–37. It is
thought that IL-1, produced by polymorphonuclear leuko-
cytes, synovial macrophages, synovial fibroblasts, or by
chondrocytes themselves, stimulates the chondrocytes to
synthesize proteases, such as MMPs and plasminogen
activator, leading to cartilage degradation. Since it is likely
that IL-1 initially exerts its effects on OA through access to
the chondrocytes from the synovial fluid34,38, it is added to
the media of monolayer chondrocyte or explant cultures of
articular cartilage to create an in vitro OA model. Cook
et al.19 have described a 3-D culture system as an in vitro
OA model that provides advantages for studying facets of
OA. In this system, the 3-D constructs represent articular
cartilage and the liquid media represent synovial fluid.
Thus, at least a subset of cell, matrix, and synovial fluid
changes that occur in OA can be investigated using this
model. There was no direct evidence for penetration of
exogenous TIMP-1 (28 kDa) and TIMP-2 (24 kDa) through
agarose gel in the present study. However, the effects of
recombinant proteins of similar molecular mass, including
TGF-β (25 kDa), on chondrocytes in agarose have been
reported39,40. Although molecular mass is not the sole
factor in determining penetration through agarose matrix,
previous studies reported that TIMP-1 was secreted into
culture media from chondrocytes cultured in agarose39,40.
The results of these studies suggest that TIMP can
penetrate agarose matrix. In addition, data from the present
study indicate significant effects of TIMP-1 and -2 on
agarose cultures, again suggesting that TIMP-1 and -2 can
penetrate the agarose matrix and exert effects on the
chondrocytes within the matrix. Therefore, a lack of
blockage of detrimental effects of IL-1β by TIMPs, seen in
the present study, cannot be attributed to the agarose
matrix. Results of the present study indicate that the 3-D
agarose culture system facilitates investigation of effects
of a potential therapeutic intervention on chondrocytes in
OA.
One can incriminate species differences with respect to
the use of human recombinant TIMPs with canine chondro-
cytes as a reason for the fact that TIMPs did not prevent
detrimental effects driven by IL-1β. However, it has been
well documented that MMP and TIMP homologs in verte-
brates are highly conserved41,42. Amino acid sequence
analyses of canine TIMP-1 and -2 show 79% homology
with human TIMP-1 and 96% homology with human
TIMP-2, respectively. For MMPs, although the canine
MMP-1 amino acid sequence is not present in the data
bank (NCBI databases), those of canine MMP-3 (fragment)
and MMP-13 are highly homologous with those of human
MMP-3 (81%) and MMP-13 (98%), respectively. In addition,
previously reported data6,21,22 support cross-reactivity
between human and canine MMPs. MMP-1, -3, and -13
have been localized in canine cartilage tissues by immuno-
histochemistry, using anti-human antibodies21,22. Pelletier
et al.6 reported imbalance between MMP and TIMP in joint
tissues from a canine OA model in which MMP inhibition by
TIMP was determined by an inhibitory assay between
collagenase purified from human OA synovium and
extracted canine TIMP. Based on these data and previous
reports, a lack of significant effects of TIMP on chondro-
cytes exposed to IL-1β for some outcome measures in the
present study cannot be completely attributed to species
differences.
In the study reported here, cell viability and differentiation
were maintained in the control group throughout the study
period. The IL-1β groups showed less viable chondrocytes
with lack of ECM formation more frequently than the
Fig. 9. Mean (±S.E.M.) HP concentrations in 3-D constructs per dry
weights. Concentrations of HP were measured on days 9, 15, and
24 of culture. HP contents (HP/weight) were significantly higher
in the controls than in the T2 groups at each collection time
(*P<0.05). In addition to the T2 group, IL-1β and IL/T2 had
significantly lower HP contents than the control on day 24 (*P<
0.05).
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chondrocytes cultured without added IL-1β. Both histo-
chemical and biochemical assessments revealed that GAG
production was suppressed by the addition of IL-1β. This
finding is consistent with a previous study that reported that
IL-1β inhibited proteoglycan synthesis43. Addition of
TIMP-1 or -2, at the single regimen evaluated, appeared to
have minimal effects on histologic and histochemical char-
acteristics of chondrocytes. Several functions of TIMPs
other than inhibition of ECM degradation by MMPs have
been reported, including inhibition of cell growth by pre-
venting the degradation of growth factor-binding proteins
by MMPs, blockage of cell cycle progression by upregulat-
ing p27, and regulation of cell proliferation and apoptosis by
binding to a putative cell-associated receptor44. No infor-
mation, however, is present in the literature regarding
effects of those TIMPs functions on chondrocytes, and their
relevance with respect to the pathogenesis of OA is
unclear. In the present study, TIMP-1 and -2 alone (without
IL-1β) did not cause either an increase or a decrease in cell
population, as determined by total DNA assay. It has been
reported that the number of cells, as well as DNA con-
tent (3H-thymidine uptake), are largely unchanged in 3-D
agarose culture over time26,45. It is possible that the slow
cell proliferation rate in 3-D agarose concealed TIMP’s
potential effects on cell proliferation. Cell viabilities in
groups IL/T1 and IL/T2 were not inferior to those in the
IL-1β group. However, 3-D constructs in these groups had
less toluidine blue-stained matrix and lower GAG concen-
trations compared with those cultured without IL-1β. In the
present study, we did not assess endogenous TIMP pro-
duction and cannot describe the impact of exogenous
TIMPs on endogenous TIMPs with clear evidence. How-
ever, largely unchanged results within each of non-IL-1
groups (control, TIMP-1, -2) and IL-1 groups (IL-1, IL/
TIMP-1, IL/TIMP-2) imply that the impact of endogenous
TIMPs on outcome measures used in this study is most
likely negligible in the model used. Neither TIMP-1 nor
TIMP-2 significantly alleviated the detrimental effects of
IL-1β on chondrocytes or ECM in the present study.
In spite of the observation of morphologically less viable
cells more frequently in the IL-1β group in this study, DNA
assay did not show significant differences in DNA content
among groups. This finding is consistent with the obser-
vation of monolayer-cultured chondrocytes in which IL-1β
induces morphologic changes, including shrinking of the
cells, whereas the IL-1β-induced morphologic changes are
not associated with increased levels of apoptosis and cell
death46. IL-1β is also known as an inhibitor of chondrocyte
proliferation through activation of a nitric oxide-dependent
prostaglandin E2 (PGE2) synthesis pathway47. However,
the effect of IL-1β on cell proliferation in the present study
could be insignificant because of the slow cell proliferation
nature in 3-D agarose culture. Although it is possible that
the percentage of cells that appeared less viable may not
have been great enough to cause significant differences in
total DNA content among groups, it is most likely that the
cells that appeared less viable in the present study are not
dead and the DNA is still measurable in those cells.
IL-1β caused significantly less GAG release to the liquid
media when compared with controls on day 9 in this study,
even in the presence of TIMP-1 or -2. This finding is
contrary to a previous report in which addition of a high
concentration of TIMP-1 to the culture media inhibited
IL-1β-induced GAG release to the media of bovine cartilage
explants12. In cartilage explants, IL-1β-induced GAG
release was reported to be time-dependent48. Addition of
IL-1β beginning on day 3 of 3-D culture may primarily be
inhibitory for the formation of ECM rather than destructive
to existing ECM. This may explain the lower release of
GAG into the liquid media, concomitant with suppressed
GAG production in 3-D constructs in the IL-1β-exposed
groups. Data showing no significant differences in the ratio,
liquid media GAG:corresponding 3-D GAG, substantiate
this suggestion. Therefore, it is possible that the addition of
TIMP-1 and -2 mildly inhibited IL-1β-induced matrix turn-
over suppression in the early period of the present study.
In contrast to the effects on proteoglycan synthesis and
degradation, effects of IL-1β on collagen are reported to be
less dramatic in vitro37. It has been reported that no
collagen damage occurs in alginate-cultured chondrocytes
after 2 days at 20 ng/ml IL-1β, and collagen release in
bovine nasal cartilage explants occurs only after long time
periods (>3 weeks) at relatively high concentrations of
IL-1α (50 ng/ml)37,49. Our data regarding HP production
and collagen type II immunoreactivity correspond to these
findings37,49. In the present study, HP production and
collagen type II immunoreactivity were minimally affected
by the presence of IL-1β through day 15 of 3-D culture.
However, both HP production and collagen type II immuno-
reactivity were decreased by IL-1β on day 24, and addition
of TIMP-1 or -2 did not significantly alter the effects of IL-1β
on collagen synthesis and degradation. Interestingly, ad-
dition of TIMP-2 alone (without IL-1β) resulted in signifi-
cantly lower HP contents than controls at each sample
collection time. A decrease in HP seen in the chondrocytes
treated with TIMP-2 may be a result of as yet undefined
functions of TIMP-2 that may lead to inhibition of collagen
synthesis and/or enhancement of collagen degradation.
Maximal MMP synthesis by chondrocytes has occurred
within a relatively short time period after the addition of
IL-1β in previous studies19,37. Significantly higher MMP-3
concentrations and MMP-1 immunoreactivities in the IL-1β
group in the early period of the present study agree with
previous reports. Suppression of increased MMP levels by
TIMP-1 and -2 in the present study also supports previously
reported data regarding TIMP-mediated reduction in MMP
activities9. However, the reduction in MMP levels seen in
TIMP groups in this study did not translate into protection
against the deleterious effects of IL-1β on chondrocytes
and their ECM. IL-1β has been reported to induce chondro-
cytes to produce proteinases including MMPs and aggre-
canses9. Although all MMPs present in cartilage (MMP-1,
-2, -3, -7, -8, -9, -13, and MT1-MMP) are known to be
capable of degrading the interglobular domain of the
aggrecan core protein at the Asn341-Phe342, the role of
MMPs in the catabolism of aggrecan is less clearly defined.
Recently, the role of MMPs in aggrecan degradation has
been shadowed by aggrecanases that cleave in the inter-
globular domain of aggrecan between Glu373-Ala37450,51.
Two aggrecanases, a disintegrin and metalloproteinase
with thrombospondin motifs (ADAM-TS)-4 and ADAM-TS
5, have been identified50,51. These proteinases are con-
sidered to play an important role in the breakdown of
proteoglycan aggrecan50,51. Tortorella et al.52 reported that
ADAM-TS4 and -TS5 were responsible for approximately
90% of the aggrecanase activity found in culture media
following IL-1α exposure of bovine cartilage explants.
These in vitro studies reported that in addition to the
interglobular domain of aggrecan at Glu373-Ala374, these
aggrecanases cleave aggrecan between G2 and G3 at four
additional sites, including Glu1480-Gly1481, Glu1667-Gly1668,
Glu1771-Ala1772, and Glu1871-Leu1872 (reviewed in refer-
ences 52,53). A recent study by Malfait et al.54 demon-
strated that aggrecan catabolism in OA cartilage was
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blocked by a synthetic ADAM-TS inhibitor, but not by a
synthetic MMP inhibitor. These reports suggest that pro-
teoglycan catabolism is predominantly controlled by
ADAM-TS4 and -TS5, rather than by MMPs. Other investi-
gators have reported that aggrecanase activities were not
inhibited, or were less effectively inhibited by TIMP-1, -2,
or -4 than TIMP-355,56. Therefore, the lack of inhibitory
effects by TIMP-1 or -2 on IL-1β-associated decreases in
GAG production may be explained by the presence of
uninhibited aggrecanases. In addition, it is important to
notice that proteoglycan degradation precedes collagen
degradation15,37.
Interestingly, conflicting outcomes of adenovirus-based
overexpression of TIMP-1 in two different murine arthritis
models have been reported57,58. Schett et al.57 reported
that clinical, radiographic, and histologic indicators of
arthritis of tumor necrosis factor (TNF)α in transgenic mice
were alleviated by adenoviral vector-based overexpression
of TIMP-1, while serum levels of TNFα and IL-6 remained
unchanged. However, Apparailly et al.58 reported that
adenoviral vector-based overexpression of TIMP-1 was
associated with deterioration in clinical, radiographic, and
histologic measures of arthritis, concomitant with an
increase in inflammatory cytokines in a collagen-induced
model of arthritis. Based on these data and the present
study, supraphysiologic levels of TIMP-1 may be beneficial
in TNFα-driven arthritis, yet not in immune-mediated arthri-
tis and this IL-1-based OA model. Further elucidation of
TIMP-mediated mechanisms that may lead to beneficial or
unfavorable effects in various arthritides is necessary. In
addition, it is apparent that the timing and amount of TIMP
expression must be appropriately controlled in order to
invoke beneficial effects in OA, while avoiding detrimental
sequelae.
In conclusion, addition of TIMP-1 (255 nM) and TIMP-2
(285 nM) did not cause detrimental effects to chondrocytes
in 3-D culture. Despite inhibition of MMP levels, TIMP-1
and -2 at the single concentration evaluated did not prevent
histological and biochemical alterations in chondrocytes
exposed to IL-1β. These data suggest that TIMP-1 and -2
may not be the main inhibitor to target for treatment of OA.
Since most proteases including aggrecanases and reactive
oxygen species produced by chondrocytes can be upregu-
lated by elevated levels of IL-1 and TNFα, a lack of
inhibition of the detrimental effects of IL-1β on chondro-
cytes in this study may be attributed to a lack of blockage of
those catabolic factors by TIMPs. Regulation of the signals
from these cytokines may have to be considered as a more
colligative therapeutic modality for OA.
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